NCT01706432已完成不适用
Biologic Endpoints in the Annihilation of Metastases for Oligometastasis (BEAM ON)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Change in the number of circulating tumor cells
研究概览
简要总结
This pilot clinical trial studies new ways to monitor the impact of hypofractionated image guided radiation therapy in treating patients with stage IV breast cancer. Radiation therapy uses high energy x rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically proven diagnosis of breast cancer (invasive ductal, lobular, medullary, papillary, colloid, tubular)
- •Completion of standard of care treatment for local and regional disease with no known residual
- •American Joint Committee on Cancer (AJCC) (6th edition, 2002) Stage IV ( Any T, Any N, M1) based upon the following minimum diagnostic workup:
- •History/physical examination within 8 weeks prior to registration
- •Computed tomography (CT), magnetic resonance imaging (MRI) and/or positron emission tomography (PET) CT of the whole body within 60 days prior to registration
- •MRI of the brain, if clinically indicated
- •Documentation of 1-5 sites of metastatic tumor; each individual site of tumor must be =< 10 cm or < 500 cc volume and amenable to radiation therapy as seen on standard imaging (CT, MRI, bone scan)
- •Pathology from at least one metastatic site confirming breast primary is recommended
- •Zubrod performance status =< 2 (Karnofsky >= 60%)
- •Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
- •Platelets >= 100,000 cells/mm^3
- •Hemoglobin >= 8.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)
- •Total bilirubin within institutional limits
- •Albumin > 2.9 g/dl
- •Alkaline phosphatase < 2.5x upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
- •Room air saturation (saturated oxygen [Sa02]) > 90%
- •Life expectancy > 3 months
- •Patient complete study specific informed consent process and sign consent form prior to study entry
- •Patients with prior metastatic treatment are eligible if they have been disease free for > 3 years; participants may receive hormonal and Herceptin treatment at any time
排除标准
- •Patients are ineligible if they have had prior treatment for their metastatic disease within 3 years
- •Prior radiotherapy that would result in overlap of radiation therapy fields
- •Co-existing or prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
- •Severe, active co-morbidity, defined as follows:
- •Clinically significant pulmonary dysfunction, cardiomyopathy, any history of clinically significant congestive heart failure (CHF), unstable angina pectoris, or cardiac arrhythmia
- •Transmural myocardial infarction within the last 6 months
- •Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
- •Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
- •Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol
- •Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive; protocol-specific requirements may also exclude immunocompromised patients
- •Pregnancy, breast feeding or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during treatment and for at least three months following completion; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
- •Prior treatment with anti-angiogenic therapy
- •Significant atelectasis such that CT definition of the gross tumor volume (GTV) is difficult to determine
- •Exudative, bloody or cytologically malignant effusions
- •Evidence of pleural or pericardial effusion prior to study start; patients with pleural effusion that is transudative, cytologically negative, and non-bloody are eligible; if a pleural effusion is too small for diagnostic thoracentesis, the patient will be eligible
结局指标
主要结局
Change in the number of circulating tumor cells
时间窗: At baseline, 3-4 weeks post-treatment, and every 9-12 weeks for one year
次要结局
- Progression free survival(5 years)
- Overall survival(5 years)
- Side effects of hypofractionated image guided radiotherapy(During treatment (about 21 days))
- Number of patients with IRDS in tumor sample(Day 1)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
不适用
Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand TherapyCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate CancerNCT03596710Jonsson Comprehensive Cancer Center
已完成
不适用
Diffusion-weighted Imaging Study in Cancer of the OvaryPeritoneal MetastasesOvarian CancerNCT01505829Institute of Cancer Research, United Kingdom134
招募中
不适用
Fluorescence Guided Surgery in Breast Cancer - The MARGIN-2 StudyBreast Cancer InvasiveBreast CancerNCT05939310University Medical Center Groningen70
已完成
2 期
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the ProstateProstate CancerNCT00809991Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins91
尚未招募
不适用
Miami "RADAR" TrialMetastatic Epidural Spinal Cord CompressionSpinal Cord CompressionNCT06077071University of Miami10